Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
OBJECTIVE
The objectives of the study were to characterise the pharmacokinetics and assess the tolerability of duloxetine in healthy Chinese subjects after single and multiple oral 60 mg dosing.


METHODS
This was a single-centre, double-blind, randomised, placebo-controlled, single-period study in healthy native Chinese subjects. A total of 32 subjects, 19 men (14 on duloxetine, 5 on placebo) and 13 women (10 on duloxetine, 3 on placebo) between the ages of 20 and 39 years, participated in the study. Duloxetine 60 mg (enteric-coated pellets in a capsule) was given orally once on day 1 and once daily on days 4 to 9. Sequential blood samples were collected over 72 hours after the dose on days 1 and 9, and a predose sample was obtained on days 7 and 8. Duloxetine concentrations in plasma were determined by a validated liquid chromatography-tandem mass spectrometry method. The tolerability evaluation included a physical examination, vital signs, adverse event monitoring and clinical laboratory evaluations.


RESULTS
Duloxetine disposition on oral administration is characterised by a one-compartment pharmacokinetic model. Duloxetine is well absorbed, with a median time of maximum plasma concentration at 6 and 4 hours following single and multiple dosing, respectively. At steady state, the mean apparent oral clearance (CL(ss)/F), mean apparent volume of distribution (V(ss)/F) and mean terminal elimination half-life (t((1/2))) were 86.8 L/h, 1570L and 11 hours, respectively. CL/F and V(ss)/F on single dosing were not statistically significantly different (p > 0.05) compared with multiple dosing. The linearity index, calculated as the ratio of the area under the plasma concentration-time curve (AUC) during the dosing interval tau at steady state (AUC(tau)(,ss)) to the AUC from time zero to infinity after single dosing (AUC(infinity,single dose)) was 1.15 (coefficient of variation 35.7%). The accumulation in duloxetine exposure was estimated to be 50% on multiple dosing compared with single dosing, consistent with the t((1/2)) and dosing interval (24 hours). The pharmacokinetic parameters of duloxetine in Chinese subjects were not statistically significantly different from those reported previously in Caucasian and Japanese subjects. There were no clinically significant adverse events, abnormal safety laboratory data or vital sign changes reported.


CONCLUSIONS
Duloxetine pharmacokinetics in healthy Chinese subjects given a 60 mg once-daily dosing regimen were well characterised and consistent with known duloxetine pharmacokinetics in healthy Caucasian and Japanese subjects. Both single dosing and multiple once-daily dosing of duloxetine 60 mg were well tolerated by healthy Chinese subjects in this study.
Tianmei
Si
S
Peking University Institute of Mental Health, Beijing, China.
Knadler
Mary Pat
MP
Lim
Ming T
MT
Yeo
Kwee Poo
KP
Teng
Leyan
L
Liang
Shu
S
Pan
Alan X
AX
Lobo
Evelyn D
ED
D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D002681:China; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D000068736:Duloxetine Hydrochloride; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D009325:Nausea / Q000139:chemically induced; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D012737:Sex Factors; D013876:Thiophenes / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D014839:Vomiting / Q000139:chemically induced
D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes
Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6
15177457
Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70
15589385
Curr Pharm Des. 2005;11(12):1475-93
15892657
Br J Clin Pharmacol. 2004 May;57(5):652-6
15089819
Pain. 2005 Dec 15;119(1-3):5-15
16298061
Clin Pharmacol Ther. 2003 Mar;73(3):170-7
12621382
Br J Clin Pharmacol. 2007 Mar;63(3):310-4
17380590
Pain Med. 2005 Sep-Oct;6(5):346-56
16266355
Clin Ther. 2005 Aug;27(8):1126-43
16199241
Int J Clin Pharmacol Res. 2003;23(1):31-5
14621071
IARC Sci Publ. 1999;(148):173-95
10493258
J Clin Pharmacol. 2000 Feb;40(2):161-7
10664922
Clin Chim Acta. 2007 May 1;380(1-2):100-5
17316589
Ther Drug Monit. 1996 Oct;18(5):586-91
8885124
J Urol. 2003 Oct;170(4 Pt 1):1259-63
14501737
Int J Neuropsychopharmacol. 1998 Dec;1(2):173-185
11281961
Drug Metab Dispos. 2003 Sep;31(9):1142-50
12920170